Profitability Ratios
| Ratio |
Value |
| GP Margin |
93.4% |
| EBIT Margin |
-776.0% |
| EBITDA Margin |
-776.0% |
| Operating Margin |
-776.0% |
| Pretax Margin |
-738.5% |
| Cont. Ops Margin |
-739.4% |
| Net Margin |
-739.4% |
| Bottom Line Margin |
-739.4% |
Liquidity Ratios
| Ratio |
Value |
| Current Ratio |
8.88 |
| Quick Ratio |
8.83 |
| Solvency Ratio |
-4.007 |
| Cash Ratio |
2.75 |
Valuation Ratios
| Ratio |
Value |
| Price/Earnings |
|
| PEG Ratio |
-0.16 |
| Forward PEG |
-0.16 |
| Price/Book |
4.37 |
| Price/Sales |
42.66 |
| Price/FCF |
-5.50 |
| Price/Op Cash Flow |
-5.57 |
Debt Ratios
| Ratio |
Value |
| Debt/Assets |
0.0571 |
| Debt/Equity |
0.0679 |
| Debt/Capital |
0.0635 |
| Long-Term Debt/Capital |
0.0000 |
| Financial Leverage |
1.19 |
Cash Flow Ratios
| Ratio |
Value |
| Working Capital Turnover |
0.10 |
| Operating Cash Flow Ratio |
-6.485 |
| Operating Cash Flow/Sales |
-765.4% |
| Free Cash Flow/Operating Cash Flow |
101.4% |
Coverage Ratios
| Ratio |
Value |
| Debt Service Coverage |
7385.24 |
| Interest Coverage |
7376.7879 |
| Short-Term Operating Cash Flow Coverage |
0.00 |
| Operating Cash Flow Coverage |
-11.56 |
| Capital Expenditure Coverage |
-73.20 |
| Dividend + Capital Expenditure Coverage |
-73.20 |
Dividend Ratios
| Ratio |
Value |
| Payout Ratio |
0.0000% |
| Dividend Yield |
0.0000% |
| Dividend Yield % |
0.0000% |
| Dividend Per Share |
0.0000 |
Per Share Ratios
| Ratio |
Value |
| Revenue/Share |
0.43 |
| EPS |
-3.167 |
| Debt/Share |
0.2831 |
| Cash/Share |
4.18 |
| Book Value/Share |
4.18 |
| Tangible BV/Share |
4.18 |
| Equity/Share |
4.18 |
| Operating Cash Flow/Share |
-3.278 |
| Capital Expenditure/Share |
0.045 |
| FCF/Share |
-3.323 |
Other Ratios
| Ratio |
Value |
| Net Income/Earnings Before Tax |
1.001 |
| Earnings Before Tax/EBIT |
0.952 |
| Price/Fair Value |
4.37 |
| Debt/Market Cap |
0.0000 |
| Effective Tax Rate |
-0.1% |
| Enterprise Value Multiple |
-5.16 |
EYPT - EyePoint Pharmaceuticals, Inc.